Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.345 USD | -3.93% | +8.47% | +8.47% |
Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.47% | 293M | |
+3.27% | 106B | |
+7.02% | 23.47B | |
-14.97% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-10.08% | 16.78B | |
+5.75% | 14.41B | |
+35.16% | 12.86B | |
+319.18% | 8.78B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Piper Sandler Upgrades Akebia Therapeutics to Overweight From Neutral, Adjusts Price Target to $4 From $2